51
|
de Vries RMJM, Doveston RG, Meijer FA, Brunsveld L. Elucidation of an Allosteric Mode of Action for a Thienopyrazole RORγt Inverse Agonist. ChemMedChem 2020; 15:561-565. [PMID: 32053744 PMCID: PMC7187189 DOI: 10.1002/cmdc.202000044] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Indexed: 12/14/2022]
Abstract
The demand for allosteric targeting of nuclear receptors is high, but examples are limited, and structural information is scarce. The retinoic acid-related orphan receptor gamma t (RORγt) is an important transcriptional regulator for the differentiation of T helper 17 cells for which the first, and some of the most promising, examples of allosteric nuclear receptor modulation have been reported and structurally proven. In a 2015 patent, filed by the pharmaceutical company Glenmark, a new class of small molecules was reported that act as potent inverse agonists for RORγt. A compound library around the central thienopyrazole scaffold captured a clear structure-activity relationship, but the binding mechanism of this new class of RORγt modulators has not been elucidated. Using a combination of biochemical and X-ray crystallography studies, here the allosteric mechanism for the inverse agonism for the most potent compound, classified in the patent as "example 13", is reported, providing a strongly desired additional example of allosteric nuclear receptor targeting.
Collapse
Affiliation(s)
- Rens M. J. M. de Vries
- Department of Biomedical Engineering and Institute for Complex Molecular SystemsEindhoven University of TechnologyDen Dolech 25612 AZEindhovenThe Netherlands
| | - Richard G. Doveston
- Department of Biomedical Engineering and Institute for Complex Molecular SystemsEindhoven University of TechnologyDen Dolech 25612 AZEindhovenThe Netherlands
- Leicester Institute of Structural and Chemical Biology and Department of ChemistryUniversity of LeicesterUniversity RoadLeicesterLE1 7RHUK
| | - Femke A. Meijer
- Department of Biomedical Engineering and Institute for Complex Molecular SystemsEindhoven University of TechnologyDen Dolech 25612 AZEindhovenThe Netherlands
| | - Luc Brunsveld
- Department of Biomedical Engineering and Institute for Complex Molecular SystemsEindhoven University of TechnologyDen Dolech 25612 AZEindhovenThe Netherlands
| |
Collapse
|
52
|
Wang X, Yang Y, Ren D, Xia Y, He W, Wu Q, Zhang J, Liu M, Du Y, Ren C, Li B, Shen J, Zhang Y. JQ1, a bromodomain inhibitor, suppresses Th17 effectors by blocking p300-mediated acetylation of RORγt. Br J Pharmacol 2020; 177:2959-2973. [PMID: 32060899 DOI: 10.1111/bph.15023] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Revised: 01/15/2020] [Accepted: 01/27/2020] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND AND PURPOSE Th17 cells play critical roles in chronic inflammation, including fibrosis. Histone acetyltransferase p300, a bromodomain-containing protein, acetylates RORγt and promotes Th17 cell development. The bromodomain inhibitor JQ1 was shown to alleviate Th17-mediated pathologies, but the underlying mechanism remains unclear. We hypothesized that JQ1 suppresses the response of Th17 cells by impairing p300-mediated acetylation of RORγt. EXPERIMENTAL APPROACH The effect of JQ1 on p300-mediated acetylation of RORγt was investigated in HEK293T (overexpressing Flag-p300 and Myc-RORγt) and human Th17 cells through immunoprecipitation and western blotting. To determine the regions of p300 responsible for JQ1-mediated suppression of HAT activity, we performed HAT assays on recombinant p300 fragments with/without the bromodomain, after exposure to JQ1. Additionally, the effect of JQ1 on p300-mediated acetylation of RORγt and Th17 cell function was verified in vivo, using murine Schistosoma-induced fibrosis models. Liver injury was assessed by histopathological examination and measurement of serum enzyme levels. Expression of Th17 effectors was detected by qRT-PCR, whereas IL-17- and RORγt-positive granuloma cells were detected by FACS. KEY RESULTS JQ1 impaired p300-mediated RORγt acetylation in human Th17 and HEK293T cells. JQ1 failed to suppress the acetyltransferase activity of p300 fragments lacking the bromodomain. JQ1 treatment attenuated Schistosoma-induced fibrosis in mice, by inhibiting RORγt acetylation and IL-17 expression. CONCLUSIONS AND IMPLICATIONS JQ1 impairs p300-mediated RORγt acetylation, thus reducing the expression of RORγt target genes, including Th17-specific cytokines. JQ1-mediated inhibition of p300 acetylase activity requires the p300 bromodomain. Strategies targeting p300 may provide new therapeutic approaches for controlling Th17-related diseases.
Collapse
Affiliation(s)
- Xiunan Wang
- Department of Microbiology and Parasitology, Anhui Provincial Laboratory of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, Anhui Medical University, Hefei, Anhui, China
| | - Yan Yang
- Department of Pathophysiology, School of Basic Medical Science, Anhui Medical University, Hefei, Anhui, China
| | - Dandan Ren
- Department of Pathophysiology, School of Basic Medical Science, Anhui Medical University, Hefei, Anhui, China.,Department of Pathology, Hefei BOE Hospital, Hefei, Anhui, China
| | - Yuanyuan Xia
- Department of Microbiology and Parasitology, Anhui Provincial Laboratory of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, Anhui Medical University, Hefei, Anhui, China
| | - Wenguang He
- Department of Pathophysiology, School of Basic Medical Science, Anhui Medical University, Hefei, Anhui, China
| | - Qingsi Wu
- Department of Microbiology and Parasitology, Anhui Provincial Laboratory of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, Anhui Medical University, Hefei, Anhui, China
| | - Junling Zhang
- Department of Microbiology and Parasitology, Anhui Provincial Laboratory of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, Anhui Medical University, Hefei, Anhui, China
| | - Miao Liu
- Department of Microbiology and Parasitology, Anhui Provincial Laboratory of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, Anhui Medical University, Hefei, Anhui, China
| | - Yinan Du
- Department of Microbiology and Parasitology, Anhui Provincial Laboratory of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, Anhui Medical University, Hefei, Anhui, China
| | - Cuiping Ren
- Department of Microbiology and Parasitology, Anhui Provincial Laboratory of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, Anhui Medical University, Hefei, Anhui, China
| | - Bin Li
- Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, Shanghai, China
| | - Jijia Shen
- Department of Microbiology and Parasitology, Anhui Provincial Laboratory of Microbiology and Parasitology, Anhui Key Laboratory of Zoonoses, Anhui Medical University, Hefei, Anhui, China
| | - Yuxia Zhang
- Department of Pathophysiology, School of Basic Medical Science, Anhui Medical University, Hefei, Anhui, China
| |
Collapse
|
53
|
Claudia CD, María-Elena VH, Josué VE, María-Carmen BC, Alain-Raimundo RO, Martha-Estrella GP. Small molecules under development for psoriasis: on the road to the individualized therapies. Arch Dermatol Res 2020; 312:611-627. [PMID: 32172339 DOI: 10.1007/s00403-020-02056-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Accepted: 02/26/2020] [Indexed: 02/06/2023]
Abstract
Psoriasis is an incurable cutaneous illness characterized by the presence of well-delimited reddish plaques and silvery-white dry scales. So far, there is a limited understanding of its pathogenesis, though recent discoveries on the immunological, genetic and molecular aspects of this disease have significantly contributed to the identification of new targets and the development of novel drugs. Despite these advances, many patients are still dissatisfied, so to improve patient satisfaction, reliability, and clinical outcomes, the individualization of the treatments for this disease becomes a necessity. This review summarizes recent findings related to psoriasis pathogenesis and describes new small molecules and targets recently identified as promising for treatments. Additionally, the current status, challenges and the future directions for achieving individualized therapy for this disease and the need for more collaborative studies are discussed. The individualization of treatments for psoriasis, rather than a goal, is analyzed as a process where a dynamic integration between the needs and characteristics of the patients, the pharmacological progress, and the clinical decisions takes place.
Collapse
Affiliation(s)
- Cervantes-Durán Claudia
- Escuela Nacional de Estudios Superiores Campus Morelia, Universidad Nacional Autónoma de México, Morelia, Michoacán, Mexico
| | | | - Valentín-Escalera Josué
- Instituto de Investigaciones Químico-Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Edif B-1, Ciudad Universitaria, Francisco J. Mújica, s/n, 58030, Morelia, Michoacán, Mexico
| | | | | | - García-Pérez Martha-Estrella
- Instituto de Investigaciones Químico-Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Edif B-1, Ciudad Universitaria, Francisco J. Mújica, s/n, 58030, Morelia, Michoacán, Mexico.
| |
Collapse
|
54
|
RORγt may Influence the Microenvironment of Thyroid Cancer Predicting Favorable Prognosis. Sci Rep 2020; 10:4142. [PMID: 32139737 PMCID: PMC7058012 DOI: 10.1038/s41598-020-60280-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 02/07/2020] [Indexed: 11/09/2022] Open
Abstract
We aimed to investigate the role of RORγt (Retinoic acid-related orphan receptor gamma) in the tumor microenvironment of differentiated thyroid carcinoma. We retrospectively analyzed 56 patients (48 papillary and 8 follicular thyroid carcinomas). Immunohistochemical expression of RORγt was compared to other immune markers previously investigated by our group, clinical and pathological information. All patients presented cytoplasmic expression of RORγt in thyroid tumor cells. Seven (12.5%) patients presented no nuclear expression of RORγt. Positivity was few (up to 10%) in 14 patients; 10 to 50% in 5 patients (8.9%); and more than 50% in 30 patients (53.6%). Nuclear RORγt positivity was associated with absence of distant metastasis at diagnosis (p = 0.013) and the need of less cumulative doses of radioactive iodine (p = 0.039). Patients whose tumors were positive for nuclear RORγt presented higher 10-years relapse-free survival rate than those patients who were negative for RORγt (p = 0.023). We classified the patients according to the clustering of immunological immunohistochemical markers. We were able to distinguish a subset (A) of 38 patients who presented high expression of nuclear RORγt and tended to be scarce in proinflammatory immune markers. Other 16 patients integrated a second subset (B) whose tumor microenvironment accumulated proinflammatory markers and presented low expression of nuclear nuclear RORγt. Distant metastasis at diagnosis were more frequent among patients from cluster B than from cluster A (p = 0.008). Our results reinforce that the expression of RORγt together with other immune markers might help predict the prognosis of patients with thyroid cancer and help individualize clinical management.
Collapse
|
55
|
Zhang H, Lapointe BT, Anthony N, Azevedo R, Cals J, Correll CC, Daniels M, Deshmukh S, van Eenenaam H, Ferguson H, Hegde LG, Karstens WJ, Maclean J, Miller JR, Moy LY, Simov V, Nagpal S, Oubrie A, Palte RL, Parthasarathy G, Sciammetta N, van der Stelt M, Woodhouse JD, Trotter BW, Barr K. Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases. ACS Med Chem Lett 2020; 11:114-119. [PMID: 32071676 DOI: 10.1021/acsmedchemlett.9b00431] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Accepted: 01/09/2020] [Indexed: 12/23/2022] Open
Abstract
The clinical success of anti-IL-17 monoclonal antibodies (i.e., Cosentyx and Taltz) has validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear hormone receptor RORγt is a master regulator of Th17 cells and affects the production of a host of cytokines, including IL-17A, IL-17F, IL-22, IL-26, and GM-CSF. Substantial interest has been spurred across both academia and industry to seek small molecules suitable for RORγt inhibition. A variety of RORγt inhibitors have been reported in the past few years, the majority of which are orthosteric binders. Here we disclose the discovery and optimization of a class of inhibitors, which bind differently to an allosteric binding pocket. Starting from a weakly active hit 1, a tool compound 14 was quickly identified that demonstrated superior potency, selectivity, and off-target profile. Further optimization focused on improving metabolic stability. Replacing the benzoic acid moiety with piperidinyl carboxylate, modifying the 4-aza-indazole core in 14 to 4-F-indazole, and incorporating a key hydroxyl group led to the discovery of 25, which possesses exquisite potency and selectivity, as well as an improved pharmacokinetic profile suitable for oral dosing.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Gopal Parthasarathy
- Computational and Structural Chemistry, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | | | | | | | | | | |
Collapse
|
56
|
Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases. Eur J Med Chem 2020; 187:111984. [DOI: 10.1016/j.ejmech.2019.111984] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2019] [Revised: 12/11/2019] [Accepted: 12/17/2019] [Indexed: 11/19/2022]
|
57
|
Meijer FA, Doveston RG, de Vries RMJM, Vos GM, Vos AAA, Leysen S, Scheepstra M, Ottmann C, Milroy LG, Brunsveld L. Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists. J Med Chem 2019; 63:241-259. [PMID: 31821760 PMCID: PMC6956242 DOI: 10.1021/acs.jmedchem.9b01372] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
![]()
Retinoic acid receptor-related orphan receptor γt
(RORγt) is a nuclear receptor associated with the pathogenesis
of autoimmune diseases. Allosteric inhibition of RORγt is conceptually
new, unique for this specific nuclear receptor, and offers advantages
over traditional orthosteric inhibition. Here, we report a highly
efficient in silico-guided approach that led to the discovery of novel
allosteric RORγt inverse agonists with a distinct isoxazole
chemotype. The the most potent compound, 25 (FM26), displayed submicromolar inhibition in a coactivator recruitment
assay and effectively reduced IL-17a mRNA production in EL4 cells,
a marker of RORγt activity. The projected allosteric mode of
action of 25 was confirmed by biochemical experiments
and cocrystallization with the RORγt ligand binding domain.
The isoxazole compounds have promising pharmacokinetic properties
comparable to other allosteric ligands but with a more diverse chemotype.
The efficient ligand-based design approach adopted demonstrates its
versatility in generating chemical diversity for allosteric targeting
of RORγt.
Collapse
Affiliation(s)
- Femke A Meijer
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| | - Richard G Doveston
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands.,Leicester Institute of Structural and Chemical Biology and Department of Chemistry , University of Leicester , University Road , Leicester LE1 7RH , U.K
| | - Rens M J M de Vries
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| | - Gaël M Vos
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| | - Alex A A Vos
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| | - Seppe Leysen
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| | - Marcel Scheepstra
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| | - Christian Ottmann
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| | - Lech-Gustav Milroy
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| | - Luc Brunsveld
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 AZ Eindhoven , The Netherlands
| |
Collapse
|
58
|
Sato A, Fukase Y, Kono M, Ochida A, Oda T, Sasaki Y, Ishii N, Tomata Y, Fukumoto S, Imai YN, Uga K, Shibata A, Yamasaki M, Nakagawa H, Shirasaki M, Skene R, Hoffman I, Sang B, Snell G, Shirai J, Yamamoto S. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists. ChemMedChem 2019; 14:1917-1932. [DOI: 10.1002/cmdc.201900416] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 10/04/2019] [Indexed: 11/10/2022]
Affiliation(s)
- Ayumu Sato
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Yoshiyuki Fukase
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Tri-Institutional Therapeutics Discovery Institute, Inc. 413 East 69th Street New York NY 10021 USA
| | - Mitsunori Kono
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Atsuko Ochida
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Tsuneo Oda
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Yusuke Sasaki
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Naoki Ishii
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Yoshihide Tomata
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Shoji Fukumoto
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Japan Tobacco Inc.Central Pharmaceutical Research Institute 1-1 Murasaki-cho Takatsuki, Osaka 569-1125 Japan
| | - Yumi N. Imai
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Chordia Therapeutics Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Keiko Uga
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Akira Shibata
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Masashi Yamasaki
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Hideyuki Nakagawa
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Mikio Shirasaki
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-Chome, Fujisawa Kanagawa 251-0012 Japan
| | - Robert Skene
- Takeda California, Inc.10410 Science Center Drive San Diego CA 92121 USA
| | - Isaac Hoffman
- Takeda California, Inc.10410 Science Center Drive San Diego CA 92121 USA
| | - Bi‐Ching Sang
- Takeda California, Inc.10410 Science Center Drive San Diego CA 92121 USA
| | - Gyorgy Snell
- Takeda California, Inc.10410 Science Center Drive San Diego CA 92121 USA
| | - Junya Shirai
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
- Cardurion Pharmaceuticals K.K. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| | - Satoshi Yamamoto
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company Ltd. 26-1, Muraokahigashi 2-chome, Fujisawa Kanagawa 251-8555 Japan
| |
Collapse
|
59
|
Yuan CM, Chen HH, Sun NN, Ma XJ, Xu J, Fu W. Molecular dynamics simulations on RORγt: insights into its functional agonism and inverse agonism. Acta Pharmacol Sin 2019; 40:1480-1489. [PMID: 31316175 DOI: 10.1038/s41401-019-0259-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2019] [Accepted: 05/21/2019] [Indexed: 11/10/2022] Open
Abstract
The retinoic acid receptor-related orphan receptor (ROR) γt receptor is a member of nuclear receptors, which is indispensable for the expression of pro-inflammatory cytokine IL-17. RORγt has been established as a drug target to design and discover novel treatments for multiple inflammatory and immunological diseases. It is important to elucidate the molecular mechanisms of how RORγt is activated by an agonist, and how the transcription function of RORγt is interrupted by an inverse agonist. In this study we performed molecular dynamics simulations on four different RORγt systems, i.e., the apo protein, protein bound with agonist, protein bound with inverse agonist in the orthosteric-binding pocket, and protein bound with inverse agonist in the allosteric-binding pocket. We found that the orthosteric-binding pocket in the apo-form RORγt was mostly open, confirming that apo-form RORγt was constitutively active and could be readily activated (ca. tens of nanoseconds scale). The tracked data from MD simulations supported that RORγt could be activated by an agonist binding at the orthosteric-binding pocket, because the bound agonist helped to enhance the triplet His479-Tyr502-Phe506 interactions and stabilized H12 structure. The stabilized H12 helped RORγt to form the protein-binding site, and therefore made the receptor ready to recruit a coactivator molecule. We also showed that transcription function of RORγt could be interrupted by the binding of inverse agonist at the orthosteric-binding pocket or at the allosteric-binding site. After the inverse agonist was bound, H12 either structurally collapsed, or reorientated to a different position, at which the presumed protein-binding site was not able to be formed.
Collapse
|
60
|
Marcoux D, Duan JJW, Shi Q, Cherney RJ, Srivastava AS, Cornelius L, Batt DG, Liu Q, Beaudoin-Bertrand M, Weigelt CA, Khandelwal P, Vishwakrishnan S, Selvakumar K, Karmakar A, Gupta AK, Basha M, Ramlingam S, Manjunath N, Vanteru S, Karmakar S, Maddala N, Vetrichelvan M, Gupta A, Rampulla RA, Mathur A, Yip S, Li P, Wu DR, Khan J, Ruzanov M, Sack JS, Wang J, Yarde M, Cvijic ME, Li S, Shuster DJ, Borowski V, Xie JH, McIntyre KW, Obermeier MT, Fura A, Stefanski K, Cornelius G, Hynes J, Tino JA, Macor JE, Salter-Cid L, Denton R, Zhao Q, Carter PH, Dhar TGM. Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy. J Med Chem 2019; 62:9931-9946. [PMID: 31638797 DOI: 10.1021/acs.jmedchem.9b01369] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
RORγt is an important nuclear receptor that regulates the production of several pro-inflammatory cytokines such as IL-17 and IL-22. As a result, RORγt has been identified as a potential target for the treatment of various immunological disorders such as psoriasis, psoriatic arthritis, and inflammatory bowel diseases. Structure and computer-assisted drug design led to the identification of a novel series of tricyclic RORγt inverse agonists with significantly improved in vitro activity in the reporter (Gal4) and human whole blood assays compared to our previous chemotype. Through careful structure activity relationship, several potent and selective RORγt inverse agonists have been identified. Pharmacokinetic studies allowed the identification of the lead molecule 32 with a low peak-to-trough ratio. This molecule showed excellent activity in an IL-2/IL-23-induced mouse pharmacodynamic study and demonstrated biologic-like efficacy in an IL-23-induced preclinical model of psoriasis.
Collapse
Affiliation(s)
- David Marcoux
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - James J-W Duan
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Qing Shi
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Robert J Cherney
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Anurag S Srivastava
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Lyndon Cornelius
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Douglas G Batt
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Qingjie Liu
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Myra Beaudoin-Bertrand
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Carolyn A Weigelt
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Purnima Khandelwal
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Sureshbabu Vishwakrishnan
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Kumaravel Selvakumar
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Ananta Karmakar
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Arun Kumar Gupta
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Mushkin Basha
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Sridharan Ramlingam
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Naveen Manjunath
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Sridhar Vanteru
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Sukhen Karmakar
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Nageswara Maddala
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Muthalagu Vetrichelvan
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Anuradha Gupta
- Department of Discovery Synthesis , Biocon Bristol-Myers Squibb Research Centre , Biocon Park, Bommasandra IV Phase, Jigani Link Road , Bengaluru 560099 , India
| | - Richard A Rampulla
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Arvind Mathur
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Shiuhang Yip
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Peng Li
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Dauh-Rurng Wu
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Javed Khan
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Max Ruzanov
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - John S Sack
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Jinhong Wang
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Melissa Yarde
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Mary Ellen Cvijic
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Sha Li
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - David J Shuster
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Virna Borowski
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Jenny H Xie
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Kim W McIntyre
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Mary T Obermeier
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Aberra Fura
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Kevin Stefanski
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Georgia Cornelius
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - John Hynes
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Joseph A Tino
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - John E Macor
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Luisa Salter-Cid
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Rex Denton
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Qihong Zhao
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - Percy H Carter
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| | - T G Murali Dhar
- Research and Development , Bristol-Myers Squibb , 3551 Lawrenceville Rd , Princeton , New Jersey 08540 , United States
| |
Collapse
|
61
|
Sun N, Guo H, Wang Y. Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present). Expert Opin Ther Pat 2019; 29:663-674. [DOI: 10.1080/13543776.2019.1655541] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Nannan Sun
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China
| | - Huimin Guo
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China
| | - Yonghui Wang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China
| |
Collapse
|
62
|
Jetten AM, Cook DN. (Inverse) Agonists of Retinoic Acid-Related Orphan Receptor γ: Regulation of Immune Responses, Inflammation, and Autoimmune Disease. Annu Rev Pharmacol Toxicol 2019; 60:371-390. [PMID: 31386594 DOI: 10.1146/annurev-pharmtox-010919-023711] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Retinoic acid-related orphan receptor γt (RORγt) functions as a ligand-dependent transcription factor that regulates multiple proinflammatory genes and plays a critical role in several inflammatory and autoimmune diseases. Various endogenous and synthetic RORγ (inverse) agonists have been identified that regulate RORγ transcriptional activity, including many cholesterol intermediates and oxysterols. Changes in cholesterol biosynthesis and metabolism can therefore have a significant impact on the generation of oxysterol RORγ ligands and, consequently, can control RORγt activity and inflammation. These observations contribute to a growing literature that connects cholesterol metabolism to the regulation of immune responses and autoimmune disease. Loss of RORγ function in knockout mice and in mice treated with RORγ inverse agonists results in reduced production of proinflammatory cytokines, such as IL-17A/F, and increased resistance to autoimmune disease in several experimental rodent models. Thus, RORγt inverse agonists might provide an attractive therapeutic approach to treat a variety of autoimmune diseases.
Collapse
Affiliation(s)
- Anton M Jetten
- Cell Biology Section, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA;
| | - Donald N Cook
- Immunogenetics Section, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
| |
Collapse
|
63
|
Gauld SB, Jacquet S, Gauvin D, Wallace C, Wang Y, McCarthy R, Goess C, Leys L, Huang S, Su Z, Edelmayer R, Wetter J, Salte K, McGaraughty SP, Argiriadi MA, Honore P, Luccarini JM, Bressac D, Desino K, Breinlinger E, Cusack K, Potin D, Kort ME, Masson PJ. Inhibition of Interleukin-23–Mediated Inflammation with a Novel Small Molecule Inverse Agonist of RORγt. J Pharmacol Exp Ther 2019; 371:208-218. [DOI: 10.1124/jpet.119.258046] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 07/18/2019] [Indexed: 01/06/2023] Open
|
64
|
Lu Z, Duan JJW, Xiao H, Neels J, Wu DR, Weigelt CA, Sack JS, Khan J, Ruzanov M, An Y, Yarde M, Karmakar A, Vishwakrishnan S, Baratam V, Shankarappa H, Vanteru S, Babu V, Basha M, Kumar Gupta A, Kumaravel S, Mathur A, Zhao Q, Salter-Cid LM, Carter PH, Murali Dhar T. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists. Bioorg Med Chem Lett 2019; 29:2265-2269. [DOI: 10.1016/j.bmcl.2019.06.036] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 06/11/2019] [Accepted: 06/19/2019] [Indexed: 11/25/2022]
|
65
|
de Oliveira Boldrini V, Dos Santos Farias A, Degasperi GR. Deciphering targets of Th17 cells fate: From metabolism to nuclear receptors. Scand J Immunol 2019; 90:e12793. [PMID: 31141182 DOI: 10.1111/sji.12793] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Revised: 05/19/2019] [Accepted: 05/24/2019] [Indexed: 12/17/2022]
Abstract
Evidence indicates that reprogramming of metabolism is critically important for the differentiation of CD4 + T lymphocytes, and the manipulation of metabolic pathways in these cells may shape their fate and function. Distinct subgroups from T lymphocytes, such as Th17, adopt specific metabolic programmes to support their needs. Some important metabolic reactions, such as glycolysis, oxidative phosphorylation, are considered important for the differentiation of these lymphocytes. Since their discovery nearly a decade ago, Th17 lymphocytes have received significant attention because of their role in the pathology of several immune-mediated inflammatory diseases such as multiple sclerosis. In this review, it will be discussed as the involvement of T cell metabolism and as metabolic reprogramming in activated T cells dictates fate decisions to Th17. The involvement of nuclear receptors such as RORyt e PPARs in the induction of Th17 cells was also discussed. Understanding the metabolic pathways involved in the differentiation of the distinct subgroups of T lymphocytes helps in the design of promising therapeutic proposals.
Collapse
Affiliation(s)
- Vinícius de Oliveira Boldrini
- Autoimmune Research Laboratory, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.,Neuroimmunology Unit, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.,National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Rio de Janeiro, Brazil
| | - Alessandro Dos Santos Farias
- Autoimmune Research Laboratory, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.,Neuroimmunology Unit, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.,National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Rio de Janeiro, Brazil
| | | |
Collapse
|
66
|
Chiang PC, Nagapudi K, Liu J, Crawford JJ, Zbieg JR, Plise E, Deng Y. An Integrated Analysis of Solid Form Change Impact on Solubility and Permeability: Case Study of Oral Exposure in Rats of an RAR Related Orphan Receptor C Inhibitor. J Pharm Sci 2019; 108:2256-2263. [DOI: 10.1016/j.xphs.2019.01.031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Revised: 01/29/2019] [Accepted: 01/31/2019] [Indexed: 11/15/2022]
|
67
|
Essential Kinases and Transcriptional Regulators and Their Roles in Autoimmunity. Biomolecules 2019; 9:biom9040145. [PMID: 30974919 PMCID: PMC6523499 DOI: 10.3390/biom9040145] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2019] [Revised: 04/04/2019] [Accepted: 04/05/2019] [Indexed: 12/11/2022] Open
Abstract
Kinases and transcriptional regulators are fundamental components of cell signaling that are expressed on many types of immune cells which are involved in secretion of cytokines, cell proliferation, differentiation, and apoptosis. Both play important roles in biological responses in health as well as in illnesses such as the autoimmune diseases which comprise at least 80 disorders. These diseases are caused by complex genetic and environmental interactions that lead to a breakage of immunologic tolerance and a disruption of the balance between self-reactive cells and regulatory cells. Kinases or transcriptional regulatory factors often have an abnormal expression in the autoimmune cells that participate in the pathogenesis of autoimmune disease. These abnormally expressed kinases or transcriptional regulators can over-activate the function of self-reactive cells to produce inflammatory cytokines or down-regulate the activity of regulatory cells, thus causing autoimmune diseases. In this review we introduce five kinds of kinase and transcriptional regulator related to autoimmune diseases, namely, members of the Janus kinase (JAK) family (JAK3 and/or tyrosine kinase 2 (TYK2)), fork head box protein 3 (Foxp3), the retinoic acid-related orphan receptor gamma t (RORγt), and T-box expressed in T cells (T-bet) factors. We also provide a mechanistic insight into how these kinases and transcriptional regulators affect the function of the immune cells related to autoimmune diseases, as well as a description of a current drug design targeting these kinases and transcriptional regulators. Understanding their exact role helps offer new therapies for control of the inflammatory responses that could lead to clinical improvement of the autoimmune diseases.
Collapse
|
68
|
Zhang Y, Wu X, Xue X, Li C, Wang J, Wang R, Zhang C, Wang C, Shi Y, Zou L, Li Q, Huang Z, Hao X, Loomes K, Wu D, Chen HW, Xu J, Xu Y. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. J Med Chem 2019; 62:4716-4730. [DOI: 10.1021/acs.jmedchem.9b00327] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Yan Zhang
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510530, China
| | - Xishan Wu
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510530, China
| | - Xiaoqian Xue
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- School of Life Science, Huizhou University, Huizhou 516007, China
| | - Chenchang Li
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
| | - Junjian Wang
- School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
| | - Rui Wang
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
| | - Cheng Zhang
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- School of Pharmaceutical Sciences, Jilin University, No.1266 Fujin Road, Chaoyang District, Changchun, Jilin 130021, China
| | - Chao Wang
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510530, China
| | - Yudan Shi
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510530, China
| | - Lingjiao Zou
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510530, China
| | - Qiu Li
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- University of Chinese Academy of Sciences, No. 19 Yuquan Road, Beijing 100049, China
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510530, China
| | | | - Xiaojuan Hao
- Manufacturing, Commonwealth Scientific and Industrial Research Organization (CSIRO), Clayton, Vic 3168, Australia
| | - Kerry Loomes
- School of Biological Sciences & Maurice Wilkins Centre, University of Auckland, Auckland 1010, New Zealand
| | - Donghai Wu
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
| | | | - Jinxin Xu
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
| | - Yong Xu
- Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou Medical University, Guangzhou 510530, China
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510530, China
| |
Collapse
|
69
|
Meijer FA, Leijten-van de Gevel IA, de Vries RMJM, Brunsveld L. Allosteric small molecule modulators of nuclear receptors. Mol Cell Endocrinol 2019; 485:20-34. [PMID: 30703487 DOI: 10.1016/j.mce.2019.01.022] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 01/23/2019] [Accepted: 01/25/2019] [Indexed: 02/08/2023]
Abstract
Nuclear Receptors (NRs) are multi-domain proteins, whose natural regulation occurs via ligands for a classical, orthosteric, binding pocket and via intra- and inter-domain allosteric mechanisms. Allosteric modulation of NRs via synthetic small molecules has recently emerged as an interesting entry to address the need for small molecules targeting NRs in pathology, via novel modes of action and with beneficial profiles. In this review the general concept of allosteric modulation in drug discovery is first discussed, serving as a background and inspiration for NRs. Subsequently, the review focuses on examples of small molecules that allosterically modulate NRs, with a strong focus on structural information and the ligand binding domain. Recently discovered nanomolar potent allosteric site NR modulators are catapulting allosteric targeting of NRs to the center of attention. The obtained insights serve as a basis for recommendations for the next steps to take in allosteric small molecular targeting of NRs.
Collapse
Affiliation(s)
- Femke A Meijer
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612AZ, Eindhoven, the Netherlands
| | - Iris A Leijten-van de Gevel
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612AZ, Eindhoven, the Netherlands
| | - Rens M J M de Vries
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612AZ, Eindhoven, the Netherlands
| | - Luc Brunsveld
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612AZ, Eindhoven, the Netherlands.
| |
Collapse
|
70
|
Tian J, Sun N, Yu M, Gu X, Xie Q, Shao L, Liu J, Liu L, Wang Y. Discovery of N-indanyl benzamides as potent RORγt inverse agonists. Eur J Med Chem 2019; 167:37-48. [DOI: 10.1016/j.ejmech.2019.01.082] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 01/27/2019] [Accepted: 01/30/2019] [Indexed: 01/01/2023]
|
71
|
Duan JJW, Lu Z, Jiang B, Stachura S, Weigelt CA, Sack JS, Khan J, Ruzanov M, Galella MA, Wu DR, Yarde M, Shen DR, Shuster DJ, Borowski V, Xie JH, Zhang L, Vanteru S, Gupta AK, Mathur A, Zhao Q, Foster W, Salter-Cid LM, Carter PH, Dhar TGM. Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists. ACS Med Chem Lett 2019; 10:367-373. [PMID: 30891142 DOI: 10.1021/acsmedchemlett.9b00010] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Accepted: 02/25/2019] [Indexed: 01/12/2023] Open
Abstract
A new phenyl (3-phenylpyrrolidin-3-yl)sulfone series of RORγt inverse agonists was discovered utilizing the binding conformation of previously reported bicyclic sulfonamide 1. Through a combination of structure-based design and structure-activity relationship studies, a polar set of amides at N1-position of the pyrrolidine ring and perfluoroisopropyl group at para-position of the 3-phenyl group were identified as critical structural elements to achieve high selectivity against PXR, LXRα, and LXRβ. Further optimization led to the discovery of (1R,4r)-4-((R)-3-((4-fluorophenyl)sulfonyl)-3-(4-(perfluoropropan-2-yl)phenyl)pyrrolidine-1-carbonyl)cyclohexane-1-carboxylic acid (26), which displayed excellent selectivity, desirable liability and pharmacokinetic properties in vitro, and a good pharmacokinetic profile in mouse. Oral administration of 26 demonstrated dose-dependent inhibition of IL-17 production in a mouse IL-2/IL-23-induced pharmacodynamic model and biologic-like efficacy in an IL-23-induced mouse acanthosis model.
Collapse
Affiliation(s)
- James J.-W. Duan
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Zhonghui Lu
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Bin Jiang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sylwia Stachura
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Carolyn A. Weigelt
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John S. Sack
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Javed Khan
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Max Ruzanov
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Michael A. Galella
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Dauh-Rurng Wu
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Melissa Yarde
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Ding-Ren Shen
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David J. Shuster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Virna Borowski
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Jenny H. Xie
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Lisa Zhang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sridhar Vanteru
- Bristol-Myers Squibb-Biocon Research Center, Bangalore 560099, India
| | - Arun Kumar Gupta
- Bristol-Myers Squibb-Biocon Research Center, Bangalore 560099, India
| | - Arvind Mathur
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Qihong Zhao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - William Foster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Luisa M. Salter-Cid
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Percy H. Carter
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - T. G. Murali Dhar
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
72
|
Damm-Ganamet KL, Arora N, Becart S, Edwards JP, Lebsack AD, McAllister HM, Nelen MI, Rao NL, Westover L, Wiener JJM, Mirzadegan T. Accelerating Lead Identification by High Throughput Virtual Screening: Prospective Case Studies from the Pharmaceutical Industry. J Chem Inf Model 2019; 59:2046-2062. [DOI: 10.1021/acs.jcim.8b00941] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
| | | | | | | | | | | | - Marina I. Nelen
- Discovery Sciences, Janssen Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477, United States
| | | | - Lori Westover
- Discovery Sciences, Janssen Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477, United States
| | | | | |
Collapse
|
73
|
Philips RL, McCue SA, Rajcula MJ, Shapiro VS. Cutting Edge: HDAC3 Protects Double-Positive Thymocytes from P2X7 Receptor-Induced Cell Death. THE JOURNAL OF IMMUNOLOGY 2019; 202:1033-1038. [PMID: 30626694 DOI: 10.4049/jimmunol.1801438] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Accepted: 12/10/2018] [Indexed: 11/19/2022]
Abstract
Intricate life-versus-death decisions are programmed during T cell development, and the regulatory mechanisms that coordinate their activation and repression are still under investigation. In this study, HDAC3-deficient double-positive (DP) thymocytes exhibit a severe decrease in numbers. The thymic cortex is rich in ATP, which is released by macrophages that clear apoptotic DP thymocytes that fail to undergo positive selection. We demonstrate that HDAC3 is required to repress expression of the purinergic receptor P2X7 to prevent DP cell death. HDAC3-deficient DP thymocytes upregulate the P2X7 receptor, increasing sensitivity to ATP-induced cell death. P2rx7/HDAC3-double knockout mice show a partial rescue in DP cell number. HDAC3 directly binds to the P2rx7 enhancer, which is hyperacetylated in the absence of HDAC3. In addition, RORγt binds to the P2rx7 enhancer and promotes P2X7 receptor expression in the absence of HDAC3. Therefore, HDAC3 is a critical regulator of DP thymocyte survival and is required to suppress P2X7 receptor expression.
Collapse
|
74
|
Kim J, Song J, Ji HD, Yoo EK, Lee JE, Lee SB, Oh JM, Lee S, Hwang JS, Yoon H, Kim DS, Lee SJ, Jeong M, Lee S, Kim KH, Choi HS, Lee SW, Park KG, Lee IK, Kim SH, Hwang H, Jeon YH, Chin J, Cho SJ. Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer. J Med Chem 2019; 62:1837-1858. [DOI: 10.1021/acs.jmedchem.8b01296] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Jina Kim
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Jaeyoung Song
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | | | | | - Jae-Eon Lee
- Department of Biomaterials Science, College of Natural Resources and Life Science/Life and Industry Convergence Research Institute, Pusan National University, Pusan 50463, South Korea
| | - Sang Bong Lee
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | | | | | - Ji Sun Hwang
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Heeseok Yoon
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Dong-Su Kim
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Su-Jeong Lee
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Minseon Jeong
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Sungwoo Lee
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Kyung-Hee Kim
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Hueng-Sik Choi
- National Creative Research Initiatives Center for Nuclear Receptor Signals and Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju 61186, South Korea
| | | | - Keun-Gyu Park
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 41944, South Korea
| | - In-Kyu Lee
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 41944, South Korea
| | - Seong Heon Kim
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Hayoung Hwang
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Yong Hyun Jeon
- Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Jungwook Chin
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| | - Sung Jin Cho
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, South Korea
| |
Collapse
|
75
|
Yukawa T, Nara Y, Kono M, Sato A, Oda T, Takagi T, Sato T, Banno Y, Taya N, Imada T, Shiokawa Z, Negoro N, Kawamoto T, Koyama R, Uchiyama N, Skene R, Hoffman I, Chen CH, Sang B, Snell G, Katsuyama R, Yamamoto S, Shirai J. Design, Synthesis, and Biological Evaluation of Retinoic Acid-Related Orphan Receptor γt (RORγt) Agonist Structure-Based Functionality Switching Approach from In House RORγt Inverse Agonist to RORγt Agonist. J Med Chem 2019; 62:1167-1179. [DOI: 10.1021/acs.jmedchem.8b01181] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Tomoya Yukawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshi Nara
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Mitsunori Kono
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Ayumu Sato
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tsuneo Oda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Terufumi Takagi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Takayuki Sato
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshihiro Banno
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Naohiro Taya
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Takashi Imada
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Zenyu Shiokawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Nobuyuki Negoro
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tetsuji Kawamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Ryokichi Koyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Noriko Uchiyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Robert Skene
- Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Isaac Hoffman
- Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Chien-Hung Chen
- Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - BiChing Sang
- Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Gyorgy Snell
- Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Ryosuke Katsuyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Satoshi Yamamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Junya Shirai
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
76
|
Takeda Y, Kang HS, Jetten AM. Analysis of the Transcriptional Activity of Retinoic Acid-Related Orphan Receptors (RORs) and Inhibition by Inverse Agonists. Methods Mol Biol 2019; 1966:193-202. [PMID: 31041748 DOI: 10.1007/978-1-4939-9195-2_15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Here, we describe several assays to analyze the transcriptional activity of retinoic acid-related orphan receptors (RORs) and the effect of inverse agonists on their activity. One assay measures the effect of an inverse agonist on the transcriptional activation of a luciferase reporter by RORs in a Tet-On cell system. A mammalian two-hybrid assay analyzes the interaction of the ROR ligand binding domain with a coactivator peptide. Two additional assays examine the effect of an inverse agonist on the activation of a luciferase reporter under control of the promoter of the ROR target gene, IL17, and on ROR-mediated activation using a mammalian monohybrid assay.
Collapse
Affiliation(s)
- Yukimasa Takeda
- National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
| | - Hong Soon Kang
- National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
| | - Anton M Jetten
- National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA.
| |
Collapse
|
77
|
Sun N, Yuan C, Ma X, Wang Y, Gu X, Fu W. Molecular Mechanism of Action of RORγt Agonists and Inverse Agonists: Insights from Molecular Dynamics Simulation. Molecules 2018; 23:molecules23123181. [PMID: 30513894 PMCID: PMC6321388 DOI: 10.3390/molecules23123181] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 11/25/2018] [Accepted: 11/26/2018] [Indexed: 02/07/2023] Open
Abstract
As an attractive drug-target, retinoic acid receptor-related orphan receptor-gamma-t (RORγt) has been employed widely to develop clinically relevant small molecular modulators as potent therapy for autoimmune disease and cancer, but its molecular mechanism of action (MOA) remains unclear. In the present study, we designed and discovered two novel RORγt ligands that are similar in structure, but different in efficacy. Using fluorescence resonance energy transfer (FRET) assay, compound 1 was identified as an agonist with an EC50 of 3.7 μM (max. act.: 78%), while compound 2 as an inverse agonist with an IC50 value of 2.0 μM (max. inh.: 61%). We performed molecular dynamics (MD) simulations, and elucidated the MOA of RORγt agonist and inverse agonist. Through the analyses of our MD results, we found that, after RORγt is bound with the agonist 1, the side chain of Trp317 stays in the gauche- conformation, and thus helps to form the hydrogen bond, His479-Trp502, and a large hydrophobic network among H11, H11′, and H12. All these interactions stabilize the H12, and helps the receptor recruit the coactivator. When the RORγt is bound with the inverse agonist 2, the side chain of Trp317 is forced to adopt the trans conformation, and these presumed interactions are partially destroyed. Taken together, the critical role of residue Trp317 could be viewed as the driving force for the activation of RORγt.
Collapse
Affiliation(s)
- Nannan Sun
- Department of Medicinal Chemistry and Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China.
| | - Congmin Yuan
- Department of Medicinal Chemistry and Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China.
| | - Xiaojun Ma
- Department of Medicinal Chemistry and Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China.
| | - Yonghui Wang
- Department of Medicinal Chemistry and Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China.
| | - Xianfeng Gu
- Department of Medicinal Chemistry and Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China.
| | - Wei Fu
- Department of Medicinal Chemistry and Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China.
| |
Collapse
|
78
|
Wang Y, Liu H. A Drug with Lipophilicity-Dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-Related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-Inflammatory Agent. J Med Chem 2018; 61:10412-10414. [DOI: 10.1021/acs.jmedchem.8b01545] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Yibing Wang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Hong Liu
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| |
Collapse
|
79
|
Sasaki Y, Odan M, Yamamoto S, Kida S, Ueyama A, Shimizu M, Haruna T, Watanabe A, Okuno T. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003. Bioorg Med Chem Lett 2018; 28:3549-3553. [DOI: 10.1016/j.bmcl.2018.09.032] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2018] [Revised: 09/21/2018] [Accepted: 09/25/2018] [Indexed: 11/30/2022]
|
80
|
Schnute ME, Wennerstål M, Alley J, Bengtsson M, Blinn JR, Bolten CW, Braden T, Bonn T, Carlsson B, Caspers N, Chen M, Choi C, Collis LP, Crouse K, Färnegårdh M, Fennell KF, Fish S, Flick AC, Goos-Nilsson A, Gullberg H, Harris PK, Heasley SE, Hegen M, Hromockyj AE, Hu X, Husman B, Janosik T, Jones P, Kaila N, Kallin E, Kauppi B, Kiefer JR, Knafels J, Koehler K, Kruger L, Kurumbail RG, Kyne RE, Li W, Löfstedt J, Long SA, Menard CA, Mente S, Messing D, Meyers MJ, Napierata L, Nöteberg D, Nuhant P, Pelc MJ, Prinsen MJ, Rhönnstad P, Backström-Rydin E, Sandberg J, Sandström M, Shah F, Sjöberg M, Sundell A, Taylor AP, Thorarensen A, Trujillo JI, Trzupek JD, Unwalla R, Vajdos FF, Weinberg RA, Wood DC, Xing L, Zamaratski E, Zapf CW, Zhao Y, Wilhelmsson A, Berstein G. Discovery of 3-Cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. J Med Chem 2018; 61:10415-10439. [DOI: 10.1021/acs.jmedchem.8b00392] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
| | | | | | | | | | | | | | - Tomas Bonn
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Bo Carlsson
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Nicole Caspers
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Ming Chen
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Chulho Choi
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | | | | | - Andrew C. Flick
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | - Steven E. Heasley
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | - Bolette Husman
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Tomasz Janosik
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | | | | | | | - Björn Kauppi
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | | | - John Knafels
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Konrad Koehler
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Lars Kruger
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Ravi G. Kurumbail
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Robert E. Kyne
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | - Carol A. Menard
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | | | | | - Philippe Nuhant
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | - Maria Sjöberg
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | - Aron Sundell
- Karo Bio AB (now Karo Pharma AB), 111 48 Stockholm, Sweden
| | | | | | - John I. Trujillo
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | - Felix F. Vajdos
- Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | | |
Collapse
|
81
|
Narjes F, Xue Y, von Berg S, Malmberg J, Llinas A, Olsson RI, Jirholt J, Grindebacke H, Leffler A, Hossain N, Lepistö M, Thunberg L, Leek H, Aagaard A, McPheat J, Hansson EL, Bäck E, Tångefjord S, Chen R, Xiong Y, Hongbin G, Hansson TG. Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design. J Med Chem 2018; 61:7796-7813. [DOI: 10.1021/acs.jmedchem.8b00783] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Linda Thunberg
- Early Product Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-43183 Mölndal, Sweden
| | - Hanna Leek
- Early Product Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-43183 Mölndal, Sweden
| | | | | | | | | | | | - Rongfeng Chen
- Pharmaron Beijing Company, Ltd., Taihe Road, BDA, Beijing 100176, PR China
| | - Yao Xiong
- Pharmaron Beijing Company, Ltd., Taihe Road, BDA, Beijing 100176, PR China
| | - Ge Hongbin
- Pharmaron Beijing Company, Ltd., Taihe Road, BDA, Beijing 100176, PR China
| | | |
Collapse
|
82
|
Gabr MT, Abdel-Raziq MS. Structure-Based Design and Synthesis of Fluorene Derivatives as Novel RORγt Inverse Agonists. Chem Biodivers 2018; 15:e1800244. [PMID: 29935095 DOI: 10.1002/cbdv.201800244] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 06/22/2018] [Indexed: 01/21/2023]
Abstract
A new series of fluorene derivatives was designed and synthesized as novel retinoic acid receptor-related orphan receptor gamma t (RORγt) inverse agonists utilizing a molecular hybridization approach. The new compounds 10 - 15 were evaluated for their RORγt activity using biochemical FRET and cellular reporter gene assays. Moreover, the inhibitory activity of the fluorene derivatives 10 - 15 in mouse Th17 cell differentiation assay was assessed. The hybrid compound 15 that combines both fluorene and arylsulfone moieties displayed promising RORγt activity with IC50 values of 68.6 and 99.5 nm in FRET and cellular assays, respectively. In addition, molecular modeling studies were employed to investigate potential binding mode of 15 to RORγt. These results render 15 a potential lead compound for development of therapeutics for Th17-driven autoimmune diseases.
Collapse
Affiliation(s)
- Moustafa T Gabr
- Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt
| | - Mohammed S Abdel-Raziq
- Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.,School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD, 4072, Australia
| |
Collapse
|
83
|
Pandya VB, Kumar S, Sachchidanand, Sharma R, Desai RC. Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses. J Med Chem 2018; 61:10976-10995. [DOI: 10.1021/acs.jmedchem.8b00588] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Vrajesh B. Pandya
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Sanjay Kumar
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Sachchidanand
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Rajiv Sharma
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Ranjit C. Desai
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| |
Collapse
|
84
|
Kargbo RB. ROR(GMMA)T Modulating Activity for the Treatment of Cancers. ACS Med Chem Lett 2018; 9:590-591. [PMID: 30034583 DOI: 10.1021/acsmedchemlett.8b00216] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2018] [Indexed: 11/28/2022] Open
Affiliation(s)
- Robert B. Kargbo
- Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States
| |
Collapse
|
85
|
Carcache DA, Vulpetti A, Kallen J, Mattes H, Orain D, Stringer R, Vangrevelinghe E, Wolf RM, Kaupmann K, Ottl J, Dawson J, Cooke NG, Hoegenauer K, Billich A, Wagner J, Guntermann C, Hintermann S. Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model. J Med Chem 2018; 61:6724-6735. [DOI: 10.1021/acs.jmedchem.8b00529] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
86
|
Rauhamäki S, Postila PA, Lätti S, Niinivehmas S, Multamäki E, Liedl KR, Pentikäinen OT. Discovery of Retinoic Acid-Related Orphan Receptor γt Inverse Agonists via Docking and Negative Image-Based Screening. ACS OMEGA 2018; 3:6259-6266. [PMID: 30023945 PMCID: PMC6044741 DOI: 10.1021/acsomega.8b00603] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 05/31/2018] [Indexed: 05/14/2023]
Abstract
Retinoic acid-related orphan receptor γt (RORγt) has a vital role in the differentiation of T-helper 17 (TH17) cells. Potent and specific RORγt inverse agonists are sought for treating TH17-related diseases such as psoriasis, rheumatoid arthritis, and type 1 diabetes. Here, the aim was to discover novel RORγt ligands using both standard molecular docking and negative image-based screening. Interestingly, both of these in silico techniques put forward mostly the same compounds for experimental testing. In total, 11 of the 34 molecules purchased for testing were verified as RORγt inverse agonists, thus making the effective hit rate 32%. The pIC50 values for the compounds varied from 4.9 (11 μM) to 6.2 (590 nM). Importantly, the fact that the verified hits represent four different cores highlights the structural diversity of the RORγt inverse agonism and the ability of the applied screening methodologies to facilitate much-desired scaffold hopping for drug design.
Collapse
Affiliation(s)
- Sanna Rauhamäki
- Department
of Biological and Environmental Science & Nanoscience Center, University of Jyväskylä, P.O. Box 35, Jyväskylä FI-40014 University of Jyvaskyla, Finland
| | - Pekka A. Postila
- Department
of Biological and Environmental Science & Nanoscience Center, University of Jyväskylä, P.O. Box 35, Jyväskylä FI-40014 University of Jyvaskyla, Finland
| | - Sakari Lätti
- Department
of Biological and Environmental Science & Nanoscience Center, University of Jyväskylä, P.O. Box 35, Jyväskylä FI-40014 University of Jyvaskyla, Finland
- Institute
of Biomedicine, Integrative Physiology and Pharmacology, Kiinamyllynkatu 10 C6, University of Turku, FI-20520 Turku, Finland
| | - Sanna Niinivehmas
- Department
of Biological and Environmental Science & Nanoscience Center, University of Jyväskylä, P.O. Box 35, Jyväskylä FI-40014 University of Jyvaskyla, Finland
- Institute
of Biomedicine, Integrative Physiology and Pharmacology, Kiinamyllynkatu 10 C6, University of Turku, FI-20520 Turku, Finland
| | - Elina Multamäki
- Department
of Biological and Environmental Science & Nanoscience Center, University of Jyväskylä, P.O. Box 35, Jyväskylä FI-40014 University of Jyvaskyla, Finland
| | - Klaus R. Liedl
- Institute
of General, Inorganic and Theoretical Chemistry, Centre for Chemistry
and Biomedicine, University of Innsbruck, Innrain 82, A-6020 Innsbruck, Austria
| | - Olli T. Pentikäinen
- Department
of Biological and Environmental Science & Nanoscience Center, University of Jyväskylä, P.O. Box 35, Jyväskylä FI-40014 University of Jyvaskyla, Finland
- Institute
of Biomedicine, Integrative Physiology and Pharmacology, Kiinamyllynkatu 10 C6, University of Turku, FI-20520 Turku, Finland
- Institute
of General, Inorganic and Theoretical Chemistry, Centre for Chemistry
and Biomedicine, University of Innsbruck, Innrain 82, A-6020 Innsbruck, Austria
- E-mail: (O.T.P.)
| |
Collapse
|
87
|
Targeting RORs nuclear receptors by novel synthetic steroidal inverse agonists for autoimmune disorders. Bioorg Med Chem 2018; 26:1686-1704. [DOI: 10.1016/j.bmc.2018.02.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 02/01/2018] [Accepted: 02/13/2018] [Indexed: 11/19/2022]
|
88
|
Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T. Identification and biological evaluation of thiazole-based inverse agonists of RORγt. Bioorg Med Chem Lett 2018; 28:1446-1455. [DOI: 10.1016/j.bmcl.2018.03.093] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 03/30/2018] [Accepted: 03/31/2018] [Indexed: 01/07/2023]
|
89
|
Kono M, Ochida A, Oda T, Imada T, Banno Y, Taya N, Masada S, Kawamoto T, Yonemori K, Nara Y, Fukase Y, Yukawa T, Tokuhara H, Skene R, Sang BC, Hoffman ID, Snell GP, Uga K, Shibata A, Igaki K, Nakamura Y, Nakagawa H, Tsuchimori N, Yamasaki M, Shirai J, Yamamoto S. Discovery of [cis-3-({(5R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist. J Med Chem 2018; 61:2973-2988. [DOI: 10.1021/acs.jmedchem.8b00061] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Mitsunori Kono
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Atsuko Ochida
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tsuneo Oda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Takashi Imada
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshihiro Banno
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Naohiro Taya
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shinichi Masada
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tetsuji Kawamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kazuko Yonemori
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshi Nara
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshiyuki Fukase
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tomoya Yukawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hidekazu Tokuhara
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Robert Skene
- Takeda California, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Bi-Ching Sang
- Takeda California, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Isaac D. Hoffman
- Takeda California, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Gyorgy P. Snell
- Takeda California, 10410 Science Center Drive, San Diego, California 92121, United States
| | - Keiko Uga
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Akira Shibata
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Keiko Igaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshiki Nakamura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hideyuki Nakagawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Noboru Tsuchimori
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masashi Yamasaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Junya Shirai
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Satoshi Yamamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
90
|
Discovery of carbazole carboxamides as novel RORγt inverse agonists. Eur J Med Chem 2018; 148:465-476. [PMID: 29477887 DOI: 10.1016/j.ejmech.2018.02.050] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 01/29/2018] [Accepted: 02/14/2018] [Indexed: 01/12/2023]
Abstract
A novel series of carbazole carboxamides was discovered as potent RORγt inverse agonists using a scaffold hybridization strategy. Structure-activity relationship exploration on the amide linker, carbazole ring and arylsulfone moiety of the hybrid amide 3a led to identification of potent RORγt inverse agonists. Compound 6c was found to have a good RORγt activity with an IC50 of 58.5 nM in FRET assay, and reasonable inhibitory activity in mouse Th17 cell differentiation assay (58.8% inhibition at 0.3 μM). The binding mode of carbazole carboxamides in RORγt ligand binding domain was discussed.
Collapse
|
91
|
Wang Y, Cai W, Tang T, Liu Q, Yang T, Yang L, Ma Y, Zhang G, Huang Y, Song X, Orband-Miller LA, Wu Q, Zhou L, Xiang Z, Xiang JN, Leung S, Shao L, Lin X, Lobera M, Ren F. From RORγt Agonist to Two Types of RORγt Inverse Agonists. ACS Med Chem Lett 2018; 9:120-124. [PMID: 29456799 DOI: 10.1021/acsmedchemlett.7b00476] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Accepted: 01/22/2018] [Indexed: 11/28/2022] Open
Abstract
Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both "short" and "long" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While "short" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, "long" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology.
Collapse
Affiliation(s)
- Yonghui Wang
- School
of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai 201203, China
| | - Wei Cai
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Ting Tang
- School
of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai 201203, China
| | - Qian Liu
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Ting Yang
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Liuqing Yang
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Yingli Ma
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Guifeng Zhang
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Yafei Huang
- School
of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai 201203, China
| | - Xiaoxia Song
- School
of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai 201203, China
| | - Lisa A. Orband-Miller
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Qianqian Wu
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Ling Zhou
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Zhijun Xiang
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Jia-Ning Xiang
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Stewart Leung
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Liming Shao
- School
of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai 201203, China
| | - Xichen Lin
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Mercedes Lobera
- Research
and Development, GlaxoSmithKline, 200 Technology Square, Suite 602, Cambridge, Massachusetts 02139, United States
| | - Feng Ren
- Research and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| |
Collapse
|
92
|
Qiu R, Wang Y. Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Agonists as Potential Small Molecule Therapeutics for Cancer Immunotherapy. J Med Chem 2018; 61:5794-5804. [DOI: 10.1021/acs.jmedchem.7b01314] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Ruomeng Qiu
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, China
| | - Yonghui Wang
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, 201203 Shanghai, China
| |
Collapse
|
93
|
Jetten AM, Takeda Y, Slominski A, Kang HS. Retinoic acid-related Orphan Receptor γ (RORγ): connecting sterol metabolism to regulation of the immune system and autoimmune disease. CURRENT OPINION IN TOXICOLOGY 2018; 8:66-80. [PMID: 29568812 DOI: 10.1016/j.cotox.2018.01.005] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Cholesterol and its metabolites are bioactive lipids that interact with and regulate the activity of various proteins and signaling pathways that are implicated in the control of a variety of physiological and pathological processes. Recent studies revealed that retinoic acid-related orphan receptors, RORα and γ, members of the ligand-dependent nuclear receptor superfamily, exhibit quite a wide binding specificity for a number of sterols. Several cholesterol intermediates and metabolites function as natural ligands of RORα and RORγ and act as agonists or inverse agonists. Changes in cholesterol homeostasis that alter the level or type of sterol metabolites in cells, can either enhance or inhibit ROR transcriptional activity that subsequently result in changes in the physiological processes regulated by RORs, including various immune responses and metabolic pathways. Consequently, this might negatively or positively impact pathologies, in which RORs are implicated, such as autoimmune disease, inflammation, metabolic syndrome, cancer, and several neurological disorders. Best studied are the links between cholesterol metabolism, RORγt activity, and their regulation of Th17 differentiation and autoimmune disease. The discovery that Th17-dependent inflammation is significantly attenuated in RORγ-deficient mice in several experimental autoimmune disease models, initiated a search for ROR modulators that led to the identification of a number of small molecular weight RORγ inverse agonists. The inverse agonists suppress Th17 differentiation and IL-17 production and protect against autoimmunity. Together, these studies suggest that RORγt may provide an attractive therapeutic target in the management of several (inflammatory) diseases.
Collapse
Affiliation(s)
- Anton M Jetten
- Cell Biology Section, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
| | - Yukimasa Takeda
- Cell Biology Section, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
| | - Andrzej Slominski
- Department of Dermatology, Comprehensive Cancer Center Cancer Chemoprevention Program, University of Alabama at Birmingham, Birmingham, AL 35249, USA
| | - Hong Soon Kang
- Cell Biology Section, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
| |
Collapse
|
94
|
Gong H, Weinstein DS, Lu Z, Duan JJW, Stachura S, Haque L, Karmakar A, Hemagiri H, Raut DK, Gupta AK, Khan J, Camac D, Sack JS, Pudzianowski A, Wu DR, Yarde M, Shen DR, Borowski V, Xie JH, Sun H, D'Arienzo C, Dabros M, Galella MA, Wang F, Weigelt CA, Zhao Q, Foster W, Somerville JE, Salter-Cid LM, Barrish JC, Carter PH, Dhar TGM. Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity. Bioorg Med Chem Lett 2018; 28:85-93. [PMID: 29233651 DOI: 10.1016/j.bmcl.2017.12.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 11/18/2017] [Accepted: 12/04/2017] [Indexed: 02/04/2023]
Abstract
We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclinical pharmacokinetic (PK) studies.
Collapse
Affiliation(s)
- Hua Gong
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - David S Weinstein
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Zhonghui Lu
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - James J-W Duan
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Sylwia Stachura
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Lauren Haque
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Ananta Karmakar
- Bristol-Myers Squibb-Biocon Research Center, Bangalore, India
| | | | | | | | - Javed Khan
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Dan Camac
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - John S Sack
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Andrew Pudzianowski
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Dauh-Rurng Wu
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Melissa Yarde
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Ding-Ren Shen
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Virna Borowski
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Jenny H Xie
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Huadong Sun
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Celia D'Arienzo
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Marta Dabros
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Michael A Galella
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Faye Wang
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Carolyn A Weigelt
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Qihong Zhao
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - William Foster
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - John E Somerville
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Luisa M Salter-Cid
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Joel C Barrish
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Percy H Carter
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - T G Murali Dhar
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
| |
Collapse
|
95
|
Discovery of orally efficacious RORγt inverse agonists, part 1: Identification of novel phenylglycinamides as lead scaffolds. Bioorg Med Chem 2018; 26:483-500. [DOI: 10.1016/j.bmc.2017.12.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Revised: 11/30/2017] [Accepted: 12/03/2017] [Indexed: 12/31/2022]
|
96
|
Liu LF, Chen JS, Shen JY, Dou TT, Zhou J, Cai SQ, Zheng M. Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy. BRAZ J PHARM SCI 2018. [DOI: 10.1590/s2175-97902018000417349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Lun-Fei Liu
- Zhejiang University School of Medicine, China; Zhejiang University School of Medicine, China
| | - Ji-Su Chen
- Zhejiang University School of Medicine, China
| | | | | | - Jiong Zhou
- Zhejiang University School of Medicine, China
| | | | - Min Zheng
- Zhejiang University School of Medicine, China
| |
Collapse
|
97
|
Fukase Y, Sato A, Tomata Y, Ochida A, Kono M, Yonemori K, Koga K, Okui T, Yamasaki M, Fujitani Y, Nakagawa H, Koyama R, Nakayama M, Skene R, Sang BC, Hoffman I, Shirai J, Yamamoto S. Identification of novel quinazolinedione derivatives as RORγt inverse agonist. Bioorg Med Chem 2017; 26:721-736. [PMID: 29342416 DOI: 10.1016/j.bmc.2017.12.039] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 12/22/2017] [Accepted: 12/24/2017] [Indexed: 11/20/2022]
Abstract
Novel small molecules were synthesized and evaluated as retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists for the treatment of inflammatory and autoimmune diseases. A hit compound, 1, was discovered by high-throughput screening of our compound library. The structure-activity relationship (SAR) study of compound 1 showed that the introduction of a chlorine group at the 3-position of 4-cyanophenyl moiety increased the potency and a 3-methylpentane-1,5-diamide linker is favorable for the activity. The carbazole moiety of 1 was also optimized; a quinazolinedione derivative 18i suppressed the increase of IL-17A mRNA level in the lymph node of a rat model of experimental autoimmune encephalomyelitis (EAE) upon oral administration. These results indicate that the novel quinazolinedione derivatives have great potential as orally available small-molecule RORγt inverse agonists for the treatment of Th17-driven autoimmune diseases. A U-shaped bioactive conformation of this chemotype with RORγt protein was also observed.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Binding Sites
- Drug Inverse Agonism
- Encephalomyelitis, Autoimmune, Experimental/drug therapy
- Encephalomyelitis, Autoimmune, Experimental/pathology
- Encephalomyelitis, Autoimmune, Experimental/veterinary
- Female
- Humans
- Inhibitory Concentration 50
- Interleukin-17/genetics
- Interleukin-17/metabolism
- Jurkat Cells
- Molecular Docking Simulation
- Nuclear Receptor Subfamily 1, Group F, Member 3/agonists
- Nuclear Receptor Subfamily 1, Group F, Member 3/genetics
- Nuclear Receptor Subfamily 1, Group F, Member 3/metabolism
- Protein Binding/drug effects
- Protein Structure, Tertiary
- Quinazolinones/administration & dosage
- Quinazolinones/chemistry
- Quinazolinones/metabolism
- Quinazolinones/pharmacology
- Rats
- Rats, Inbred Lew
- Solubility
- Structure-Activity Relationship
- Th17 Cells/cytology
- Th17 Cells/drug effects
- Th17 Cells/metabolism
Collapse
Affiliation(s)
- Yoshiyuki Fukase
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Ayumu Sato
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
| | - Yoshihide Tomata
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Atsuko Ochida
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Mitsunori Kono
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kazuko Yonemori
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Keiko Koga
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Toshitake Okui
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masashi Yamasaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yasushi Fujitani
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hideyuki Nakagawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Ryoukichi Koyama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masaharu Nakayama
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Robert Skene
- Takeda California, Inc., 10410 Science Center Drive, San Diego, CA 92121, United States
| | - Bi-Ching Sang
- Takeda California, Inc., 10410 Science Center Drive, San Diego, CA 92121, United States
| | - Isaac Hoffman
- Takeda California, Inc., 10410 Science Center Drive, San Diego, CA 92121, United States
| | - Junya Shirai
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Satoshi Yamamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
98
|
Dhanak D, Edwards JP, Nguyen A, Tummino PJ. Small-Molecule Targets in Immuno-Oncology. Cell Chem Biol 2017; 24:1148-1160. [PMID: 28938090 DOI: 10.1016/j.chembiol.2017.08.019] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Revised: 08/04/2017] [Accepted: 08/23/2017] [Indexed: 01/12/2023]
Abstract
Advances in understanding the role and molecular mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clinical practice in the treatment of cancer. Presently, multiple biologic drugs targeting the immune checkpoint proteins PD(L)1 or CTLA4 have been approved and/or are in advanced stages of clinical development for many cancers. In addition, combination therapy with these agents and other immunomodulators is being intensively explored with the aim of improving primary response rates or prolonging overall survival. The effectiveness of cancer immunotherapy with biologics is spurring research in alternate approaches including small-molecule-mediated targeting of intracellular pathways modulating the innate and adaptive immune response. This focus of this review is on some of the key intracellular pathways where the development of a small-molecule therapeutic is attractive, tractable, and potentially synergistic with extracellular biologic-mediated immune checkpoint blockade.
Collapse
Affiliation(s)
- Dashyant Dhanak
- Discovery Sciences, Janssen Research & Development, 1400 McKean Road, P O Box 776, Spring House, PA 19477, USA.
| | - James P Edwards
- Discovery Sciences, Janssen Research & Development, 1400 McKean Road, P O Box 776, Spring House, PA 19477, USA
| | - Ancho Nguyen
- Immuno Oncology Discovery, Janssen Research & Development, 1400 McKean Road, P O Box 776, Spring House, PA 19477, USA
| | - Peter J Tummino
- Discovery Sciences, Janssen Research & Development, 1400 McKean Road, P O Box 776, Spring House, PA 19477, USA
| |
Collapse
|
99
|
Barbay JK, Cummings MD, Abad M, Castro G, Kreutter KD, Kummer DA, Maharoof U, Milligan C, Nishimura R, Pierce J, Schalk-Hihi C, Spurlino J, Tanis VM, Urbanski M, Venkatesan H, Wang A, Woods C, Wolin R, Xue X, Edwards JP, Fourie AM, Leonard K. 6-Substituted quinolines as RORγt inverse agonists. Bioorg Med Chem Lett 2017; 27:5277-5283. [PMID: 29079472 DOI: 10.1016/j.bmcl.2017.10.027] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Revised: 10/12/2017] [Accepted: 10/14/2017] [Indexed: 12/14/2022]
Abstract
We identified 6-substituted quinolines as modulators of the retinoic acid receptor-related orphan receptor gamma t (RORγt). The synthesis of this class of RORγt modulators is reported, and optimization of the substituents at the quinoline 6-position that produced compounds with high affinity for the receptor is detailed. This effort identified molecules that act as potent, full inverse agonists in a RORγt-driven cell-based reporter assay. The X-ray crystal structures of two full inverse agonists from this chemical series bound to the RORγt ligand binding domain are disclosed, and we highlight the interaction of a hydrogen-bond acceptor on the 6-position substituent of the inverse agonist with Glu379:NH as a conserved binding contact.
Collapse
Affiliation(s)
- J Kent Barbay
- Discovery Immunology, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States.
| | - Maxwell D Cummings
- Discovery Sciences, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States.
| | - Marta Abad
- Discovery Sciences, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| | - Glenda Castro
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Kevin D Kreutter
- Discovery Immunology, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| | - David A Kummer
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Umar Maharoof
- Discovery Immunology, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| | - Cynthia Milligan
- Discovery Sciences, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| | - Rachel Nishimura
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Joan Pierce
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Celine Schalk-Hihi
- Discovery Sciences, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| | - John Spurlino
- Discovery Sciences, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| | - Virginia M Tanis
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Maud Urbanski
- Discovery Immunology, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| | - Hariharan Venkatesan
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Aihua Wang
- Discovery Immunology, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| | - Craig Woods
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Ronald Wolin
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Xiaohua Xue
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - James P Edwards
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Anne M Fourie
- Discovery Immunology, Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States
| | - Kristi Leonard
- Discovery Immunology, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States
| |
Collapse
|
100
|
Slominski AT, Kim TK, Hobrath JV, Oak ASW, Tang EKY, Tieu EW, Li W, Tuckey RC, Jetten AM. Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ. J Steroid Biochem Mol Biol 2017; 173:42-56. [PMID: 27693422 PMCID: PMC5373926 DOI: 10.1016/j.jsbmb.2016.09.024] [Citation(s) in RCA: 108] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 09/17/2016] [Accepted: 09/28/2016] [Indexed: 02/07/2023]
Abstract
The classical pathway of vitamin D activation follows the sequence D3→25(OH)D3→1,25(OH)2D3 with the final product acting on the receptor for vitamin D (VDR). An alternative pathway can be started by the action of CYP11A1 on the side chain of D3, primarily producing 20(OH)D3, 22(OH)D3, 20,23(OH)2D3, 20,22(OH)2D3 and 17,20,23(OH)3D3. Some of these metabolites are hydroxylated by CYP27B1 at C1α, by CYP24A1 at C24 and C25, and by CYP27A1 at C25 and C26. The products of these pathways are biologically active. In the epidermis and/or serum or adrenals we detected 20(OH)D3, 22(OH)D3, 20,22(OH)2D3, 20,23(OH)2D3, 17,20,23(OH)3D3, 1,20(OH)2D3, 1,20,23(OH)3D3, 1,20,22(OH)3D3, 20,24(OH)2D3, 1,20,24(OH)3D3, 20,25(OH)2D3, 1,20,25(OH)3D3, 20,26(OH)2D3 and 1,20,26(OH)3D3. 20(OH)D3 and 20,23(OH)2D3 are non-calcemic, while the addition of an OH at C1α confers some calcemic activity. Molecular modeling and functional assays show that the major products of the pathway can act as "biased" agonists for the VDR with high docking scores to the ligand binding domain (LBD), but lower than that of 1,25(OH)2D3. Importantly, cell based functional receptor studies and molecular modeling have identified the novel secosteroids as inverse agonists of both RORα and RORγ receptors. Specifically, they have high docking scores using crystal structures of RORα and RORγ LBDs. Furthermore, 20(OH)D3 and 20,23(OH)2D3 have been tested in a cell model that expresses a Tet-on RORα or RORγ vector and a RORE-LUC reporter (ROR-responsive element), and in a mammalian 2-hybrid model that test interactions between an LBD-interacting LXXLL-peptide and the LBD of RORα/γ. These assays demonstrated that the novel secosteroids have ROR-antagonist activities that were further confirmed by the inhibition of IL17 promoter activity in cells overexpressing RORα/γ. In conclusion, endogenously produced novel D3 hydroxy-derivatives can act both as "biased" agonists of the VDR and/or inverse agonists of RORα/γ. We suggest that the identification of large number of endogenously produced alternative hydroxy-metabolites of D3 that are biologically active, and of possible alternative receptors, may offer an explanation for the pleiotropic and diverse activities of vitamin D, previously assigned solely to 1,25(OH)2D3 and VDR.
Collapse
MESH Headings
- Animals
- Cholesterol Side-Chain Cleavage Enzyme/metabolism
- Humans
- Hydroxycholecalciferols/metabolism
- Hydroxycholecalciferols/pharmacology
- Models, Molecular
- Nuclear Receptor Subfamily 1, Group F, Member 1/agonists
- Nuclear Receptor Subfamily 1, Group F, Member 1/metabolism
- Nuclear Receptor Subfamily 1, Group F, Member 3/agonists
- Nuclear Receptor Subfamily 1, Group F, Member 3/metabolism
- Receptors, Calcitriol/agonists
- Receptors, Calcitriol/metabolism
- Vitamins/metabolism
- Vitamins/pharmacology
Collapse
Affiliation(s)
- Andrzej T Slominski
- Department of Dermatology, USA; Comprehensive Cancer Center, Cancer Chemoprevention Program, University of Alabama at Birmingham, USA; Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, AL, 35249, USA.
| | | | - Judith V Hobrath
- Drug Discovery Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom
| | | | - Edith K Y Tang
- School of Chemistry and Biochemistry, University of Western Australia, Crawley, WA, Australia
| | - Elaine W Tieu
- School of Chemistry and Biochemistry, University of Western Australia, Crawley, WA, Australia
| | - Wei Li
- Department of Pharmaceutical Sciences University of Tennessee HSC, Memphis, TN 38163, USA
| | - Robert C Tuckey
- School of Chemistry and Biochemistry, University of Western Australia, Crawley, WA, Australia
| | - Anton M Jetten
- Cell Biology Section, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA
| |
Collapse
|